Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1995 Nov 21;92(24):10854–10858. doi: 10.1073/pnas.92.24.10854

High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas.

A B Bianchi 1, S I Mitsunaga 1, J Q Cheng 1, W M Klein 1, S C Jhanwar 1, B Seizinger 1, N Kley 1, A J Klein-Szanto 1, J R Testa 1
PMCID: PMC40529  PMID: 7479897

Abstract

Malignant mesotheliomas (MMs) are aggressive tumors that develop most frequently in the pleura of patients exposed to asbestos. In contrast to many other cancers, relatively few molecular alterations have been described in MMs. The most frequent numerical cytogenetic abnormality in MMs is loss of chromosome 22. The neurofibromatosis type 2 gene (NF2) is a tumor suppressor gene assigned to chromosome 22q which plays an important role in the development of familial and spontaneous tumors of neuroectodermal origin. Although MMs have a different histogenic derivation, the frequent abnormalities of chromosome 22 warranted an investigation of the NF2 gene in these tumors. Both cDNAs from 15 MM cell lines and genomic DNAs from 7 matched primary tumors were analyzed for mutations within the NF2 coding region. NF2 mutations predicting either interstitial in-frame deletions or truncation of the NF2-encoded protein (merlin) were detected in eight cell lines (53%), six of which were confirmed in primary tumor DNAs. In two samples that showed NF2 gene transcript alterations, no genomic DNA mutations were detected, suggesting that aberrant splicing may constitute an additional mechanism for merlin inactivation. These findings implicate NF2 in the oncogenesis of primary MMs and provide evidence that this gene can be involved in the development of tumors other than nervous system neoplasms characteristic of the NF2 disorder. In addition, unlike NF2-related tumors, MM derives from the mesoderm; malignancies of this origin have not previously been associated with frequent alterations of the NF2 gene.

Full text

PDF
10854

Images in this article

10855Fig. 1
on p.10855

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arakawa H., Hayashi N., Nagase H., Ogawa M., Nakamura Y. Alternative splicing of the NF2 gene and its mutation analysis of breast and colorectal cancers. Hum Mol Genet. 1994 Apr;3(4):565–568. doi: 10.1093/hmg/3.4.565. [DOI] [PubMed] [Google Scholar]
  2. Arpin M., Algrain M., Louvard D. Membrane-actin microfilament connections: an increasing diversity of players related to band 4.1. Curr Opin Cell Biol. 1994 Feb;6(1):136–141. doi: 10.1016/0955-0674(94)90127-9. [DOI] [PubMed] [Google Scholar]
  3. Bianchi A. B., Hara T., Ramesh V., Gao J., Klein-Szanto A. J., Morin F., Menon A. G., Trofatter J. A., Gusella J. F., Seizinger B. R. Mutations in transcript isoforms of the neurofibromatosis 2 gene in multiple human tumour types. Nat Genet. 1994 Feb;6(2):185–192. doi: 10.1038/ng0294-185. [DOI] [PubMed] [Google Scholar]
  4. Cairns P., Mao L., Merlo A., Lee D. J., Schwab D., Eby Y., Tokino K., van der Riet P., Blaugrund J. E., Sidransky D. Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science. 1994 Jul 15;265(5170):415–417. doi: 10.1126/science.8023167. [DOI] [PubMed] [Google Scholar]
  5. Cheng J. Q., Jhanwar S. C., Klein W. M., Bell D. W., Lee W. C., Altomare D. A., Nobori T., Olopade O. I., Buckler A. J., Testa J. R. p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res. 1994 Nov 1;54(21):5547–5551. [PubMed] [Google Scholar]
  6. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987 Apr;162(1):156–159. doi: 10.1006/abio.1987.9999. [DOI] [PubMed] [Google Scholar]
  7. Cote R. J., Jhanwar S. C., Novick S., Pellicer A. Genetic alterations of the p53 gene are a feature of malignant mesotheliomas. Cancer Res. 1991 Oct 1;51(19):5410–5416. [PubMed] [Google Scholar]
  8. Englefield P., Foulkes W. D., Campbell I. G. Loss of heterozygosity on chromosome 22 in ovarian carcinoma is distal to and is not accompanied by mutations in NF2 at 22q12. Br J Cancer. 1994 Nov;70(5):905–907. doi: 10.1038/bjc.1994.418. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Gibas Z., Li F. P., Antman K. H., Bernal S., Stahel R., Sandberg A. A. Chromosome changes in malignant mesothelioma. Cancer Genet Cytogenet. 1986 Feb 15;20(3-4):191–201. doi: 10.1016/0165-4608(86)90074-9. [DOI] [PubMed] [Google Scholar]
  10. Haber D. A., Park S., Maheswaran S., Englert C., Re G. G., Hazen-Martin D. J., Sens D. A., Garvin A. J. WT1-mediated growth suppression of Wilms tumor cells expressing a WT1 splicing variant. Science. 1993 Dec 24;262(5142):2057–2059. doi: 10.1126/science.8266105. [DOI] [PubMed] [Google Scholar]
  11. Hagemeijer A., Versnel M. A., Van Drunen E., Moret M., Bouts M. J., van der Kwast T. H., Hoogsteden H. C. Cytogenetic analysis of malignant mesothelioma. Cancer Genet Cytogenet. 1990 Jul 1;47(1):1–28. doi: 10.1016/0165-4608(90)90258-c. [DOI] [PubMed] [Google Scholar]
  12. Harada H., Kondo T., Ogawa S., Tamura T., Kitagawa M., Tanaka N., Lamphier M. S., Hirai H., Taniguchi T. Accelerated exon skipping of IRF-1 mRNA in human myelodysplasia/leukemia; a possible mechanism of tumor suppressor inactivation. Oncogene. 1994 Nov;9(11):3313–3320. [PubMed] [Google Scholar]
  13. Jacoby L. B., MacCollin M., Louis D. N., Mohney T., Rubio M. P., Pulaski K., Trofatter J. A., Kley N., Seizinger B., Ramesh V. Exon scanning for mutation of the NF2 gene in schwannomas. Hum Mol Genet. 1994 Mar;3(3):413–419. doi: 10.1093/hmg/3.3.413. [DOI] [PubMed] [Google Scholar]
  14. Kaiser-Kupfer M. I., Freidlin V., Datiles M. B., Edwards P. A., Sherman J. L., Parry D., McCain L. M., Eldridge R. The association of posterior capsular lens opacities with bilateral acoustic neuromas in patients with neurofibromatosis type 2. Arch Ophthalmol. 1989 Apr;107(4):541–544. doi: 10.1001/archopht.1989.01070010555030. [DOI] [PubMed] [Google Scholar]
  15. Knudson A. G. Antioncogenes and human cancer. Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):10914–10921. doi: 10.1073/pnas.90.23.10914. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Lekanne Deprez R. H., Bianchi A. B., Groen N. A., Seizinger B. R., Hagemeijer A., van Drunen E., Bootsma D., Koper J. W., Avezaat C. J., Kley N. Frequent NF2 gene transcript mutations in sporadic meningiomas and vestibular schwannomas. Am J Hum Genet. 1994 Jun;54(6):1022–1029. [PMC free article] [PubMed] [Google Scholar]
  17. Luna E. J., Hitt A. L. Cytoskeleton--plasma membrane interactions. Science. 1992 Nov 6;258(5084):955–964. doi: 10.1126/science.1439807. [DOI] [PubMed] [Google Scholar]
  18. MacCollin M., Mohney T., Trofatter J., Wertelecki W., Ramesh V., Gusella J. DNA diagnosis of neurofibromatosis 2. Altered coding sequence of the merlin tumor suppressor in an extended pedigree. JAMA. 1993 Nov 17;270(19):2316–2320. doi: 10.1001/jama.270.19.2316. [DOI] [PubMed] [Google Scholar]
  19. Martuza R. L., Eldridge R. Neurofibromatosis 2 (bilateral acoustic neurofibromatosis). N Engl J Med. 1988 Mar 17;318(11):684–688. doi: 10.1056/NEJM198803173181106. [DOI] [PubMed] [Google Scholar]
  20. Park S., Schalling M., Bernard A., Maheswaran S., Shipley G. C., Roberts D., Fletcher J., Shipman R., Rheinwald J., Demetri G. The Wilms tumour gene WT1 is expressed in murine mesoderm-derived tissues and mutated in a human mesothelioma. Nat Genet. 1993 Aug;4(4):415–420. doi: 10.1038/ng0893-415. [DOI] [PubMed] [Google Scholar]
  21. Pykett M. J., Murphy M., Harnish P. R., George D. L. The neurofibromatosis 2 (NF2) tumor suppressor gene encodes multiple alternatively spliced transcripts. Hum Mol Genet. 1994 Apr;3(4):559–564. doi: 10.1093/hmg/3.4.559. [DOI] [PubMed] [Google Scholar]
  22. Rouleau G. A., Merel P., Lutchman M., Sanson M., Zucman J., Marineau C., Hoang-Xuan K., Demczuk S., Desmaze C., Plougastel B. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature. 1993 Jun 10;363(6429):515–521. doi: 10.1038/363515a0. [DOI] [PubMed] [Google Scholar]
  23. Rouleau G. A., Wertelecki W., Haines J. L., Hobbs W. J., Trofatter J. A., Seizinger B. R., Martuza R. L., Superneau D. W., Conneally P. M., Gusella J. F. Genetic linkage of bilateral acoustic neurofibromatosis to a DNA marker on chromosome 22. Nature. 1987 Sep 17;329(6136):246–248. doi: 10.1038/329246a0. [DOI] [PubMed] [Google Scholar]
  24. Rubio M. P., Correa K. M., Ramesh V., MacCollin M. M., Jacoby L. B., von Deimling A., Gusella J. F., Louis D. N. Analysis of the neurofibromatosis 2 gene in human ependymomas and astrocytomas. Cancer Res. 1994 Jan 1;54(1):45–47. [PubMed] [Google Scholar]
  25. Ruffie P. A. Pleural mesothelioma. Curr Opin Oncol. 1991 Apr;3(2):328–334. doi: 10.1097/00001622-199104000-00014. [DOI] [PubMed] [Google Scholar]
  26. SELIKOFF I. J., CHURG J., HAMMOND E. C. RELATION BETWEEN EXPOSURE TO ASBESTOS AND MESOTHELIOMA. N Engl J Med. 1965 Mar 18;272:560–565. doi: 10.1056/NEJM196503182721104. [DOI] [PubMed] [Google Scholar]
  27. Sanger F., Nicklen S., Coulson A. R. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A. 1977 Dec;74(12):5463–5467. doi: 10.1073/pnas.74.12.5463. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Seizinger B. R., Martuza R. L., Gusella J. F. Loss of genes on chromosome 22 in tumorigenesis of human acoustic neuroma. Nature. 1986 Aug 14;322(6080):644–647. doi: 10.1038/322644a0. [DOI] [PubMed] [Google Scholar]
  29. Seizinger B. R., Rouleau G., Ozelius L. J., Lane A. H., St George-Hyslop P., Huson S., Gusella J. F., Martuza R. L. Common pathogenetic mechanism for three tumor types in bilateral acoustic neurofibromatosis. Science. 1987 Apr 17;236(4799):317–319. doi: 10.1126/science.3105060. [DOI] [PubMed] [Google Scholar]
  30. Sekido Y., Pass H. I., Bader S., Mew D. J., Christman M. F., Gazdar A. F., Minna J. D. Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res. 1995 Mar 15;55(6):1227–1231. [PubMed] [Google Scholar]
  31. Smith C. W., Patton J. G., Nadal-Ginard B. Alternative splicing in the control of gene expression. Annu Rev Genet. 1989;23:527–577. doi: 10.1146/annurev.ge.23.120189.002523. [DOI] [PubMed] [Google Scholar]
  32. Taguchi T., Jhanwar S. C., Siegfried J. M., Keller S. M., Testa J. R. Recurrent deletions of specific chromosomal sites in 1p, 3p, 6q, and 9p in human malignant mesothelioma. Cancer Res. 1993 Sep 15;53(18):4349–4355. [PubMed] [Google Scholar]
  33. Tiainen M., Tammilehto L., Mattson K., Knuutila S. Nonrandom chromosomal abnormalities in malignant pleural mesothelioma. Cancer Genet Cytogenet. 1988 Jul 15;33(2):251–274. doi: 10.1016/0165-4608(88)90035-0. [DOI] [PubMed] [Google Scholar]
  34. Trofatter J. A., MacCollin M. M., Rutter J. L., Murrell J. R., Duyao M. P., Parry D. M., Eldridge R., Kley N., Menon A. G., Pulaski K. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell. 1993 Mar 12;72(5):791–800. doi: 10.1016/0092-8674(93)90406-g. [DOI] [PubMed] [Google Scholar]
  35. Twist E. C., Ruttledge M. H., Rousseau M., Sanson M., Papi L., Merel P., Delattre O., Thomas G., Rouleau G. A. The neurofibromatosis type 2 gene is inactivated in schwannomas. Hum Mol Genet. 1994 Jan;3(1):147–151. doi: 10.1093/hmg/3.1.147. [DOI] [PubMed] [Google Scholar]
  36. Wu Y. J., Parker L. M., Binder N. E., Beckett M. A., Sinard J. H., Griffiths C. T., Rheinwald J. G. The mesothelial keratins: a new family of cytoskeletal proteins identified in cultured mesothelial cells and nonkeratinizing epithelia. Cell. 1982 Dec;31(3 Pt 2):693–703. doi: 10.1016/0092-8674(82)90324-5. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES